Dr Simon Fifer, from Community and Patient Preference Research Pty Ltd, Sydney, NSW
Community and Patient Preference Research (CaPPRe) is working with Prostate Cancer Foundation of Australia to conduct research with men who have metastatic prostate cancer. This study is sponsored by CaPPRe with funding support from Janssen-Cilag Australia Pty Ltd. Janssen will not participate in, or influence the outcomes of, this study.
CaPPRe are specialists in conducting research to determine people’s preferences. We are looking at ways to gather a large number of views from people on the benefits and risks of various treatment options. This type of research is called ‘Patient Preference Research’. It may help those who assess new treatment options to understand how people value certain benefits and risks of drugs. CaPPRe are specialists in conducting patient preference research, in this case what people value, need and expect in the treatment of metastatic prostate cancer.
The study is a 20-minute online survey: http://bit.do/PC-research
Your participation will be valuable in improving the understanding of what is important to you in the care of your prostate cancer and helping make better treatments available in Australia for prostate cancer patients. We also intend to publish the results so that others can learn from them.
Ethics approval has been granted by Bellberry Human Research Ethics Committee.
Who is this study for?
You may be eligible for this study if you are:
This study is currently recruiting participants.